Combination therapy for cancer

Abstract

This invention relates to a method of treating cancer, and particularly a method including the steps of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from a paclitaxel and docetaxel, and (ii) a compound of the formula 1

Description

FIELD OF HE INVENTION

[0001] This invention relates to a method of treating cancer.

BACKGROUND OF THE INVENTION

[0002] The compound 5,6-dimethylanthenone-4-acetic acid PMAA) is known to have significant antitumour activity against murine turmous and human turmours xenografted in immunodeficient mice. Studies have shown that this activity is largely, if not entirely, a consequence of inhibition of blood flow selectively within tumours. However, to date, DMXAA has shown little evidence of clinically viable anti-cancer activity in humans.

[0003] The applicants have now surprisingly found that simultaneous or sequential administration of both a compound of the xanthenone acetic acid class (of which DMXAA is one) and either paclitaxel or docetaxel (both compounds of the taxane class of anticancer agents) results in an increase in antitumour activity such that the anticancer effect of the combination is much larger than for either agent alone, and greatly exceeds the sum of effects of the individual agents.

[0004] With this background in mind, it was an object of the present invention to provide a method of treatment of cancer which will at least provide the public with a useful choice. SUMMARY OF THE INVENTION

[0005] Accordingly, in a first aspect, the present invention provides a method of treating cancer, the method comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from paclitaxel and docetaxel, and (ii) a compound of the formula 2

[0006] or a pharmaceutically acceptable salt or ester thereof, wherein R1, R2 and R3 are each independently selected from the group consisting of H. C1—C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1—C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy, and wherein each of R1, R2 and R3 may be present at any of the available positions 1 to 8; and wherein in each of the carbocyclic aromatic rings in formula (I), up to two of the methine (−CH=) groups may be replaced by an aza (−N=) group; and wherein any two of R1, R2 and R3 may additionally together represent the group —CH=CH—CH=CH—, such that this group, together with the carbon or nitrogen atoms to which it is attached, forms a fused 6 membered aromatic ring.

[0007] Preferably, the mammal is a human.

[0008] Preferably, the compound of formula (I) is of the formula: 3

[0009] Most preferably, the compound of formula (I) is 5,6-dimethylxanthenone-4-acetic acid, having the formula 4

[0010] In a further aspect, the present invention provides the use of a compound of the formula (I) as defined above, or a pharmaceutically acceptable salt or ester thereof, in the manufacture of a medicament for treating cancer in a mammal by sequential or simultaneous co-administration of the medicament and a compound selected from paclitaxel and docetaxel.

[0011] In still a further aspect, the present invention provides the use of a compound selected from docetaxel and paclitaxel in the manufacture of a medicament for treating cancer in a mammal by sequential or simultaneous co-administration of the medicament and a compound of the formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof.

[0012] In yet a further aspect, the present invention provides a pharmaceutical composition suitable for treating cancer, comprising a compound of the formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof, and a compound selected from paclitaxel and docetaxel, in combination with one or more pharmaceutically acceptable carriers or vehicles.

DESCRIPTION OF THE DRAWINGS

[0013] While the invention is broadly as defined above, it also includes embodiments of which the following description provides examples. These specific embodiments are described in conjunction with the accompanying drawings in which:

[0014] FIG. 1 shows representative individual tumour growth curves for female C3H/HeN mice to which DMXAA, paclitaxel and DMXAA, and paclitaxel were administered as described in Example 1 herein, as follows: A: controls, B: DMXAA (80 μmol/lcg, C: pachitaxel (42.1 μmol/kg), D: DMXAA (80 μmol/kg)+paclitaxel (31.6 μmol/kg).

DESCRIPTION OF THE INVENTION

[0015] As defined above, the present invention relates to a method of treating cancer.

[0016] The invention resides in the applicant's unexpected finding of a very large synergistic interaction between compounds of the xanthenone acetic acid class having the formula (I) as defined above and two compounds (paclitaxel and docetaxel) of the taxane class of anticancer agents. In particular, the simultaneous administration of both the compound of formula (I) 5,6-dimethylxanthenone-4-acetic acid (DMXAA), and either paclitaxel or docetaxel shows greater toxicity to the host animal than either agent alone (as determined by body weight loss and proportion of deaths) and requires modest reduction in the dose of one or other agent in the combination. However, this host toxicity interaction is much less pronounced than the increase in antitumour activity. As a result, the anticancer effect achieved is dramatically larger than for either agent alone, and greatly exceeds the sum of effects of the individual agents. The combination of 5,6-dimethylxanthenone-4-acetic acid or other compounds of the formula (I) with the taxane anticancer drugs paclitaxel and docetaxel is therefore expected to have clinical utility in cancer treatment.

[0017] The therapeutic methods of the present invention therefore comprise the step of administering to a patient, simultaneously or sequentially, either paclitaxel or docetaxel, and a compound of the formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof.

[0018] The compounds of the formula a) are known and can be prepared using methods known to those persons skilled in the art. For example, compounds of the formula (I) and their preparation are described in the following references:

[0019] Journal of Medicinal Cheistry 34(1): 217-22, January 1991;

[0020] Journal of Medicinal Chemistry 34(2): 491-6, February 1991;

[0021] Journal of Mecdcinal Chemistry 33(5): 1375-9, May 1990;

[0022] Journal of Medicinal Chemistry 34(9): 2864-70, September 1991; and

[0023] Journal of Medicinal Chemistry 32(4): 793-9, April 1989, the contents of which are incorporated herein by reference.

[0024] The taxanes paclitaxel (taxol) and docetaxel (taxotere) are also well known compounds and can likewise be prepared by methods known to those skilled in the art.

[0025] Of the compounds of formula (I) defined above, compounds of the formula (Ia) (in which the substituents R1 and R2 are at the 5- and 6-positions), are generally preferred for use in the methods of the invention. A particularly preferred compound is 5,6-dimethyLxanthenone-4-acetic acid. The preparation of this compound is described in Journal of Medicinal Chemistry 34(1): 217-22, January 1991.

[0026] The compound of formula (I) and the paclitaxel or docetaxel can be administered to a patient in any suitable form. For example, the compounds may conveniently be administered intravenously, using formulations for each compound already known in the art.

[0027] The compounds of formula (I) and the paclitaxel or docetaxel can be administered either simultaneously or sequentially, ie. the taxane can be administered either at the same time, before or after the compound of formula (I) is administered.

[0028] It is however generally preferred that the paclitaxel or docetaxel is administered first, followed by administration of the compound of formula (1) as soon as practicable, preferably within about 2-4 hours.

[0029] The invention will now be described in more detail with reference to the following non-limiting examples.

EXAMPLES

[0030] Example 1

[0031] Murine mammary carcinoma MDAH—MCa-4 tumours were grown in female C3H/HeN mice from stocks stored in liquid nitrogen at the sixth transplant generation, and were passaged and used for experiments at the eighth transplant generation. Tumours for experiments were grown by inoculating 20 μl of cell suspension (5 mg packed cells) intramuscularly in the right gastrocenmius muscle. Animals were randomised to treatment groups, and treated with drugs when the dliameter of the tumour-bearing leg reached 10-11 mm (ca 0.6 g tumour), approximately 18 days after inoculation. Drugs were administered once only, by intraperitoneal injection in phosphate buffered saline PDMAA) or chremphor (pacitaxel) using volumes of 0.01 ml/g body weight for each compound. Both compounds were administered essentially at the same time (within 1 min). Host toxicity was assessed by determination of lethality, and by measurement of body weight 4-5 days after drug treatment. The diameter of the tumour-bearing leg was measured three times weekly until values exceeded 13 mm (ca 1.4 g tumour) at which time the animals were terminated. The growth curve for each individual tumour was plotted as in FIG. 1, and the time-to-endpoint (TTE, time from treatment to endpoint) was determined for each mouse. The median and mean TTE was determined for each treatment group. The mean tumour growth delay for each group was calculated as the difference between mean TTE for treated and control groups. The statistical significance of the antitumour effects was tested using ANOVA followed by Dunnett's test to determine p values for the significance of differences between individual groups.

[0032] The data in FIG. 1 and Table 1 show that a clear increase in toxicity was seen in the combination, requirng lowering of dose from 42 μmol/kg (not demonstrably toxic for paclitaxel alone) to 31.6 μmol/kg when combined with DMAA. All mice survived in good health when the latter dose was combined with DMXAA (80 μmol/kg), with no greater weight loss than DMXAA alone. Paclitaxel alone provided little antitumour activity in this model (growth delay of 4 days at 42 μmol/kg), but activity was dramatically enhanced in the combination. Combining taxol at 31.6 μmol/kg with DMXAA provided {fraction (3/7)}cures, with a mean growth delay of 50 days (42 days longer than DMXAA alone) for the 4 tumours that recurred. Large growth delays were also seen in combination with DMXAA at the two lower taxol dose levels investigated, with one cure at 17.8 μmol/kg Table 1).

TABLE 1
Activity of Paclitaxel and DMXAA, alone and in combination, against the MDAH-MCa-4 tumour. Experimental
conditions were as specified above.
						Growth delay additional to
				% Body	Growth delay (days)a	DMXAA only (days)a
Paclitaxel	DMXAA	Expt/		Weight			P			p (rel. to
dose	dose	Group	Number of mice	change (d4-5)			(rel. To			DMXAA
(μmol/kg)	(μmol/kg)	Code	Treated	Deaths	Cures	Mean	SEM	Mean	SEM	Control)	Mean	SEM	alone)
0	0	113/A	7	0	0	2.1	1.3	0	0.9
23.7	0	113/C	7	0	0	0.4	1.3	0	1.1	1
31.6	0	113/D	7	0	0	1.9	0.8	0.1	1.7	1
42.1	0	113/E	7	0	0	0.3	1.1	4.3	1.5	0.12
0	80	113/B	7	0	0	−4.1	1.3	8.3	2.3	0.0002
17.8	80	113/Z	7	0	1	−3.8	1.3	41.7	10.0		33.4	10.3	0.046
23.7	80	113/F	7	1	0	−6.7	0.7	37.6	12.7		29.3	12.9	0.11
31.6	80	113/G	7	0	3	−3.9	1.2	50.5	12.8		42.2	13.0	0.0001
42.1	80	113/H	3	3	0
aCured mice are excluded from this analysis

EXAMPLE 2

[0033] The effect of varying the time of administration of DMXAA relative to paclitaxel was investigated using the same experimental approach as in Example 1. This experiment is currently in progress, and only an interim analysis is available (based on the median time for tumours to reach the endpoint size). This interim analysis Table 2) confirms the large interaction demonstrated in Example 1. At this time it is not possible to discrminate the magnitude of the response for the groups treated with DMXAA 1 hr before paclitaxel or 1 hr after paclitaxel or 4 hr after paclitaxel or co-administration. The response is not as large with DMXAA administered 4 hr before paclitaxel. This result demonstrates a reasonably broad time window for the interaction.

TABLE 2
Activity of Paclitaxel and DMXAA, alone and in combination, against the MDAH-MCa-4 tumour, with different
timing of administration of the two drugs. Experimental conditions were as specified above. This is an
interim analysis (animals stilt under observation). For groups with large responses more than half the animals
have tumours smaller than the endpoint size and the median is not yet determined.
						Growth
Paclitaxel	DMXAA		Expt/		% Body weight change	delay
dose	dose		Group	Number of mice	(d4-5)	(days)
(μmol/kg)	(μmol/kg)	Timing	Code	Treated	Deaths	Mean	SEM	Median
0	0		120/A	6	1	−1.2	1.6	0
0	80		120/B	7	2	−6.0	2.7	17.9
23.7	0		120/C	7	1	−0.1	4.2	3.5
23.7	80	DMXAA 4 hr	120/D	12	4	−7.4	2.4	>31
		after paclitaxel
23.7	80	DMXAA 1 hr	120/E	12	2	−5.8	3.6	>41
		after paclitaxel
23.7	80	Together	120/F	12	2	−8.6	2.2	>31
23.7	80	DMXAA 1 hr	120/G	12	0	−10.1	1.1	>32
		before
		paclitaxel
23.7	80	DMXAA 4 hr	120/H	12	2	−9.0	1.6	31
		before
		paclitaxel

EXAMPLE 3

[0034] The interaction of docetaxel with DMXAA was investigated using the same experimental approach as in Example 1, with co-inistration of both compounds in the combination. This experiment is currently in progress, and only an interim analysis is available (based on the median time for tumours to reach the endpoint size). This interim analysis (Table 3) indicates that docetaxel alone is essentially devoid of activity against the MDAH—MCa—4 tumour, but that the combination of docetaxel and DMXAA is much more active than DMXAA alone. Thus, as for paclitaxel, the activity of the combination is much greater than would be expected on the basis of the activities of the single agents.

TABLE 3
Activity of Docetaxel DMXAA, alone and in combination (co-administered), against
the MDAH-MCa-4 tumour. Experimental conditions were as specified above. This is
an interim analysis (animals still under observation). For groups with large responses
more than half the animals have tumours smaller than the endpoint size and the median
is not yet determined.
					Growth
Docetaxel	DMXAA	Expt/		% Body weight change	delay
dose	dose	Group	Number of Mice	(d4-5)	(days)
(μmol/kg)	(μmol/kg)	Code	Treated	Deaths	Mean	SEM	Median
0	0	120/J	7	1	0.58	0.74	0
0	80	120/K	7	0	−4.8	1.3	10.5
17.8	0	120/L	2	0	−1.8	1.2	−1.7
23.7	0	120/M	5	0	−4.1	1.3	0.8
13.3	80	120/N	8	0	−6.8	1.5	18
17.8	80	120/P	8	0	−7.2	1.2	>21
23.7	80	120/Q	8	0	−7.4	1.2	26

INDUSTRL APPLICATION

[0035] As wfill be apparent from the above description and examples, the present invention provides an improved method of cancer therapy which is expected to find widespread clinical utility.

[0036] Those persons skilled in the art will understand that the specific description provided thereof is exemplary only and that the present invention is not limited thereto.

Claims

1. A method of treating cancer, the method comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from paclitaxel and docetaxel, and (ii) a compound of the formula 5

2. A method as claimed in claim 1, wherein the mammal is a human.

3. A method claimed in claim 1 or 2, wherein the compound of formula (I) is of the formula 6

4. A method as claimed in claim 3, wherein the compound of formula (Ia) is 5,6-dimethylxanthenone-4acetic acid or a pharmaceutically acceptable salt or ester thereof.

5. The use of a compound of the formula (I) as defined in claim 1, or a pharmaceutically acceptable salt or ester thereof, in the manufacture of a medicament for treating cancer in a mammal by sequential or simultaneous co-administration of the medicament and a compound selected from paclitaxel and docetaxel.

6. The use of a compound selected from docetaxel and paclitaxel in the manufacture of a medicament for treating cancer in a mammal by sequential or simultaneous coadministration of the medicament and a compound of the formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or ester thereof.

7. A pharmaceutical composition suitable for treating cancer, comprising a compound of the formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or ester thereof, and a compound selected from paclitaxel and docetaxel, in combination with one or more pharmaceutically acceptable carriers or vehicles.